Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1

Wuppertal, Germany, February 25, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced superior efficacy results from a subgroup analysis of its pivotal Phase 3 trial (PRIOH-1) evaluating pritelivir vs. investigator’s choice in people living with…
- In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete lesion healing compared with 20% receiving invest… [+7429 chars]
- health
- Mar 30, 2026, 03:28 AM
- health
- Mar 30, 2026, 03:21 AM
- health
- Mar 29, 2026, 10:34 PM
- health
- Mar 29, 2026, 05:34 PM
- health
- Mar 29, 2026, 12:30 PM
- health
- Mar 29, 2026, 12:22 PM
- health
- Mar 29, 2026, 12:20 PM
- health
- Mar 29, 2026, 12:18 PM
- health
- Mar 29, 2026, 12:16 PM
- health
- Mar 29, 2026, 12:16 PM